The Relief of Chronic Pain Act of 2025 aims to improve access to non-opioid pain management drugs for chronic pain conditions under Medicare part D.

The Relief of Chronic Pain Act of 2025 amends title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs for chronic pain conditions under part D of the Medicare program. It defines qualifying non-opioid chronic pain management drugs as those approved by the Food and Drug Administration to treat chronic pain conditions, excluding those that act upon the body’s opioid receptors. These drugs must also be unique, not have therapeutic equivalents, and have a wholesale acquisition cost below the monthly specialty-tier cost threshold.

The Relief of Chronic Pain Act of 2025 aims to improve access to non-opioid pain management drugs for chronic pain conditions under Medicare part D.

The Relief of Chronic Pain Act of 2025 amends title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs for chronic pain conditions under part D of the Medicare program. It defines qualifying non-opioid chronic pain management drugs as those approved by the Food and Drug Administration to treat chronic pain conditions, excluding those that act upon the body’s opioid receptors. These drugs must also be unique, not have therapeutic equivalents, and have a wholesale acquisition cost below the monthly specialty-tier cost threshold.